Compare CCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCO | ANAB |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2005 | 2015 |
| Metric | CCO | ANAB |
|---|---|---|
| Price | $2.41 | $62.39 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $2.12 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 9.0M | 570.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 110.81 | 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,604,140,000.00 | $234,603,000.00 |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $4.26 | $52.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 6.57 | ★ 157.01 |
| 52 Week Low | $1.00 | $17.11 |
| 52 Week High | $2.43 | $73.30 |
| Indicator | CCO | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 56.57 |
| Support Level | $2.37 | $52.32 |
| Resistance Level | $2.41 | $67.69 |
| Average True Range (ATR) | 0.02 | 3.27 |
| MACD | 0.00 | 0.87 |
| Stochastic Oscillator | 50.00 | 54.78 |
Clear Channel Outdoor Holdings Inc is a provider of out-of-home advertising solutions. The company offers advertisers an opportunity to reach mass audiences across various high-traffic public spaces, by using its diverse portfolio of assets including roadside billboards, street furniture, and airport displays. Its reportable segments are; America (U.S. operations excluding airports), Airports (U.S. and Caribbean airport operations), and Other. A majority of its revenue is generated from the America segment which generates revenue from the sale of advertising on printed and digital out-of-home advertising displays such as bulletins, posters, street furniture, and others. Geographically, the company generates maximum revenue from the United States followed by Singapore.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).